EUCTR2021-001081-38-ES进行中（未招募）1 期
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants with Ornithine Transcarbamylase Deficiency - Phase 2 nested single/multiple ascending dose study of ARCT-810 in Participants with OTC Deficiency
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Must have adequate cognitive ability, in the opinion of the Investigator, to understand the investigational nature of the study and study requirements, to recall symptoms over a 1-week time period, and to give informed consent (ICF). Must be willing and able to comply with all the protocol requirements, complete all study visits and sign an ICF in accordance with institutional and regulatory guidelines.
- •2.Males and females aged 12 to 65 years inclusive, at Screening.
- •3.Documented diagnosis of late onset OTC deficiency confirmed with genetic testing. In participants not previously genetically confirmed, testing should include OTC gene sequencing and deletion/duplication testing.
- •4.No hospitalizations for metabolic decompensation within 1 year prior to the first dose of Study Drug and no clinical symptoms of hyperammonemia within 1 month prior to signing ICF.
- •5.If using nitrogen ammonia scavenger therapy, must be on a stable regimen for = 28 days prior to signing ICF.
- •6.Participant has, maintained a stable protein restricted diet and/or amino acid supplementation with no changes in calorie or protein goals and no changes in medical food and/or amino acid supplementation for at least 28 days prior to signing ICF and participant is willing to remain on the same diet for the full duration of the study. Participants may have their diet adjusted for optimization by the study dietician at the Study Center during the screening period
- •7.Good general health, aside from OTC deficiency and its complications, as determined by no clinically significant abnormal findings on medical history, clinical laboratory test results (other than ammonia concentrations and other biomarkers), vital sign measurements, 12-lead ECG results, or physical examination at Screening that, in the opinion of the Investigator or Sponsor Medical monitor, would interfere with Study Drug administration, jeopardize the safety of the participant, or impact the validity of the study results.
- •8.BMI = 18.0 – 32.0 kg/m2, inclusive for adults, and >5th percentile for adolescents =12 to 17 years old.
- •9.Participants must refrain from strenuous exercise/activity and consuming alcohol for at least 72 hours prior to study visits.
- •10.Males are eligible to participate if they agree to the following requirements during the intervention period and for at least 60 days after the last dose of study drug, which corresponds to the time needed to minimize any potential reproductive safety risk of the study drug:
- •a.Refrain from donating sperm, AND
- •b.Must agree to use a male condom when engaging in sexual relations with a female of child-bearing potential (WOCBP, defined below). In addition, a highly effective method of contraception may be considered in WOCBP partners of male participants
- •Male participants who are surgically sterile are exempt from using contraception.
- •11.Females are eligible to participate if they are not currently pregnant or breastfeeding nor planning to become pregnant or breastfeed during the study; and at least one of the following conditions applies:
- •a.Is not a woman of child-bearing potential (defined below)
- •b.Is a WOCBP and using highly effective contraceptive methods during the study intervention period and for at least 60 days after the last dose of Study Drug. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study drug.
- •A woman is considered fertile following menarche and until becoming pos
排除标准
- •1.Uncontrolled hypertension (Systolic BP > 160 and/or diastolic BP >100 mm Hg)
- •2.Any participant who develops symptoms of infection, , must be asymptomatic for at least 7 days prior to dosing on Day 1. Any participant who requires systemic antimicrobial treatment must have both discontinued antimicrobial therapy for at least 7 days and be symptom free for at least 7 days prior to dosing. The screening period may be extended, , for up to 7 days without need to repeat screening evaluations. In this instance the diet run-in period should also be extended. Participants who are not free of symptoms and/or antimicrobials for at least 7 days prior to Day 1 despite the aforementioned extension of the screening period may be rescreened once medication is complete, and their clinical condition is stable for at least 7 days.
- •3.Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. Participants with a history of other malignancies that have been treated and which have no recurrence within 5 years may also be eligible if approved by the Sponsor medical monitor
- •4.History of any OTC gene therapy or hepatocyte transplantation.
- •5.History of any organ transplant or stem cell transplant.
- •6.History of severe allergic reaction to a liposomal or PEG containing product.
- •7.Abuse of medications, illicit drugs or alcohol within 1 year prior to screening,
- •8.Use of cannabis products within 28 days prior to screening..
- •9.Blood donation of 50 to 499 mL within 30 days of Screening or of > 499 mL within 60 days of Screening
- •10.Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that, in the opinion of the Investigator or Sponsor Medical Monitor (or designee) would render a participant unsuitable for inclusion:
- •ALT or AST > 2x ULN
- •Total bilirubin > 1.5 mg/dL, unless due to documented Gilbert's syndrome in which case total bilirubin must be <3 mg/dL
- •Platelet count < 100x10^9/L
- •Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 calculated by Modification to Diet in Renal Disease [MDRD] study equation.
- •Abnormal thyroid function tests unless approved by the Sponsor Medical Monitor (or designee)
- •Presence of human immunodeficiency virus antibody, hepatitis C virus antibody, or hepatitis B surface antigen
- •11.Diabetes that is not, , adequately controlled with diet +/- antidiabetic medication.
- •12.Clinically significant anemia
- •13.Changes in maintenance therapies within 28 days prior to Day 1. Participants who require a change in maintenance therapy may be rescreened once they have been on a stable regimen for = 28 days.
- •14.Treatment with oral or systemic corticosteroids within 28 days prior to Day 1 and prohibited during the study unless required to manage an IRR.
- •15.Treatment with acetaminophen within 28 days prior to Day 1 and prohibited during the trial unless required as part of the premedication regimen or to manage IRR if ibuprofen is contraindicated.
- •16.Treatment with another investigational drug, biological agent, or device within 30-days of screening, or 5 half-lives of investigational drug, whichever is longer.
- •17.Treatment with any oligonucleotide (including siRNA) or mRNA therapy within 6 months prior to Screening. Participants who have previously received only a single dose of an oligonucleotide or mRNA as part of a clinical study may be included if a duration =3 mo
研究者
相似试验
已完成
不适用
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Lecithinized Superoxide Dismutase Nebulizer (PC-SOD NE) in Adult Patients with Moderate Idiopathic Pulmonary Fibrosisidiopathic pulmonary fibrosisJPRN-UMIN000009572TT Bio-Pharma Co., Ltd.96
已完成
不适用
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Diclofenac Sodium Eye-Drops (LT-0303) in Patients with dry eye syndromedry eye syndromeJPRN-UMIN000021601TT Bio-Pharma Co., Ltd.20
招募中
1 期
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants with Ornithine Transcarbamylase DeficiencyMedDRA version: 21.1Level: LLTClassification code 10013373Term: Disorders of urea cycle metabolismSystem Organ Class: 100000004850Ornithine transcarbamylase deficiencyEUCTR2021-001081-38-ITArcturus Therapeutics, Inc.24
已完成
2 期
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Diclofenac Sodium Eye-Drops (LT-4002) in Patients with dry eye syndromedry eye syndromeJPRN-UMIN000036467TT Bio-Pharma Co., Ltd.240
进行中（未招募）
1 期
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants with Ornithine Transcarbamylase DeficiencyMedDRA version: 26.0Level: LLTClassification code 10013373Term: Disorders of urea cycle metabolismSystem Organ Class: 100000004850Ornithine transcarbamylase deficiencyEUCTR2021-001081-38-SEArcturus Therapeutics, Inc.24